ProfileGDS5678 / 1454433_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 73% 68% 72% 66% 68% 72% 73% 69% 68% 67% 69% 67% 70% 69% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.6872273
GSM967853U87-EV human glioblastoma xenograft - Control 24.1385668
GSM967854U87-EV human glioblastoma xenograft - Control 34.6137772
GSM967855U87-EV human glioblastoma xenograft - Control 43.9863466
GSM967856U87-EV human glioblastoma xenograft - Control 54.1982968
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.4725172
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.6214873
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.2677669
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.1371768
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.0817167
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.2090769
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.0347667
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.3113270
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.2510669